PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06821497 Treatment A
Drug: PF-06821497 Treatment D
Drug: PF-06821497 Treatment B
Drug: PF-06821497 Treatment E
Drug: PF-06821497 Treatment C
Drug: PF-06821497 Treatment F

First Posted Date: 2023-03-14

Last Posted Date: 2023-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05767905

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

Active, not recruiting

Conditions: Polyarticular Juvenile Idiopathic Arthritis
Psoriatic Arthritis, Juvenile

First Posted Date: 2023-03-06

Last Posted Date: 2025-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 375

Registration Number: NCT05754710

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Phase 2

Recruiting

Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

Interventions: Drug: Inotuzumab ozogamicin
Drug: ALLR3

First Posted Date: 2023-02-28

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT05748171

Locations: 🇦🇹
St. Anna Kinderspital, Vienna, Austria
🇫🇮
Helsinki university hospital, Helsinki, Finland
🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Bruxelles-capitale, Région DE, Belgium

and more 69 locations

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

Completed

Conditions: Carcinoma, Renal Cell
Clear-cell Metastatic Renal Cell Carcinoma

Interventions: Drug: Sunitinib

First Posted Date: 2023-02-27

Last Posted Date: 2024-08-05

Lead Sponsor: Pfizer

Target Recruit Count: 376

Registration Number: NCT05745142

Locations: 🇹🇷
Pfizer, Istanbul, Turkey

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07081532
Device: Cyclosporine
Drug: Itraconazole

First Posted Date: 2023-02-27

Last Posted Date: 2023-06-27

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT05745701

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

Recruiting

Conditions: Relapse Multiple Myeloma
Refractory Multiple Myeloma

First Posted Date: 2023-02-23

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT05742217

Locations: 🇮🇹
IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy

A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: ARV-471

First Posted Date: 2023-02-17

Last Posted Date: 2025-01-27

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT05732428

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳
Jilin Province Tumor Hospital, Changchun, Jilin, China
🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Phase 2

Terminated

Conditions: Atopic Dermatitis, Unspecified
Eczema, Atopic
Atopic Dermatitis
Eczema

Interventions: Drug: Placebo
Drug: etrasimod

First Posted Date: 2023-02-17

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 58

Registration Number: NCT05732454

Locations: 🇺🇸
Tory Sullivan, Md Pa, North Miami Beach, Florida, United States
🇨🇦
CaRe Clinic, Red Deer, Alberta, Canada
🇨🇿
Pratia Pardubice a.s., Pardubice, Czechia

and more 71 locations

A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

Recruiting

Conditions: Hospital-acquired Pneumonia
Complicated Intra-abdominal Infection
Complicated Urinary Tract Infection

First Posted Date: 2023-02-17

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT05733104

Locations: 🇰🇷
Pfizer, Seoul, Gangnam-gu, Korea, Republic of

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Abrocitinib

First Posted Date: 2023-02-10

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT05721937

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy